Cargando…
A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHOD...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496465/ https://www.ncbi.nlm.nih.gov/pubmed/32501582 http://dx.doi.org/10.1002/mds.28095 |
_version_ | 1783583103064735744 |
---|---|
author | Hattori, Nobutaka Kitabayashi, Hiroki Kanda, Tomoyuki Nomura, Takanobu Toyama, Keizo Mori, Akihisa |
author_facet | Hattori, Nobutaka Kitabayashi, Hiroki Kanda, Tomoyuki Nomura, Takanobu Toyama, Keizo Mori, Akihisa |
author_sort | Hattori, Nobutaka |
collection | PubMed |
description | BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHODS: We performed a pooled analysis of data from two identical phase 2b and 3 Japanese studies of istradefylline. Logistic regression models were used to assess the association of 12 patient characteristics with favorable outcomes. RESULTS: Off time reduction and increased good on time with istradefylline provided a significantly favorable response in patients aged ≥65 years. Off time reduction was more favorable in patients with ≥8‐hour daily off time at baseline. Improvement in UPDRS Part III was favorable in patients with UPDRS Part III baseline score ≥ 20. CONCLUSIONS: Several patient factors influenced the effect of istradefylline on motor fluctuations, motor function, activities of daily living, and clinical impression. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. |
format | Online Article Text |
id | pubmed-7496465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74964652020-09-25 A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease Hattori, Nobutaka Kitabayashi, Hiroki Kanda, Tomoyuki Nomura, Takanobu Toyama, Keizo Mori, Akihisa Mov Disord Regular Issue Articles BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHODS: We performed a pooled analysis of data from two identical phase 2b and 3 Japanese studies of istradefylline. Logistic regression models were used to assess the association of 12 patient characteristics with favorable outcomes. RESULTS: Off time reduction and increased good on time with istradefylline provided a significantly favorable response in patients aged ≥65 years. Off time reduction was more favorable in patients with ≥8‐hour daily off time at baseline. Improvement in UPDRS Part III was favorable in patients with UPDRS Part III baseline score ≥ 20. CONCLUSIONS: Several patient factors influenced the effect of istradefylline on motor fluctuations, motor function, activities of daily living, and clinical impression. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. John Wiley & Sons, Inc. 2020-06-05 2020-08 /pmc/articles/PMC7496465/ /pubmed/32501582 http://dx.doi.org/10.1002/mds.28095 Text en © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Issue Articles Hattori, Nobutaka Kitabayashi, Hiroki Kanda, Tomoyuki Nomura, Takanobu Toyama, Keizo Mori, Akihisa A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease |
title | A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease |
title_full | A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease |
title_fullStr | A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease |
title_full_unstemmed | A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease |
title_short | A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease |
title_sort | pooled analysis from phase 2b and 3 studies in japan of istradefylline in parkinson's disease |
topic | Regular Issue Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496465/ https://www.ncbi.nlm.nih.gov/pubmed/32501582 http://dx.doi.org/10.1002/mds.28095 |
work_keys_str_mv | AT hattorinobutaka apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT kitabayashihiroki apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT kandatomoyuki apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT nomuratakanobu apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT toyamakeizo apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT moriakihisa apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT hattorinobutaka pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT kitabayashihiroki pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT kandatomoyuki pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT nomuratakanobu pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT toyamakeizo pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease AT moriakihisa pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease |